JP2002504505A5 - - Google Patents

Download PDF

Info

Publication number
JP2002504505A5
JP2002504505A5 JP2000533099A JP2000533099A JP2002504505A5 JP 2002504505 A5 JP2002504505 A5 JP 2002504505A5 JP 2000533099 A JP2000533099 A JP 2000533099A JP 2000533099 A JP2000533099 A JP 2000533099A JP 2002504505 A5 JP2002504505 A5 JP 2002504505A5
Authority
JP
Japan
Prior art keywords
composition
butorphanol
composition according
oil
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000533099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504505A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/004113 external-priority patent/WO1999043300A1/en
Publication of JP2002504505A publication Critical patent/JP2002504505A/ja
Publication of JP2002504505A5 publication Critical patent/JP2002504505A5/ja
Pending legal-status Critical Current

Links

JP2000533099A 1998-02-25 1999-02-25 ブトルファノール持続放出性製剤 Pending JP2002504505A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3021798A 1998-02-25 1998-02-25
US09/030,217 1998-02-25
PCT/US1999/004113 WO1999043300A1 (en) 1998-02-25 1999-02-25 Butorphanol sustained release formulations

Publications (2)

Publication Number Publication Date
JP2002504505A JP2002504505A (ja) 2002-02-12
JP2002504505A5 true JP2002504505A5 (cg-RX-API-DMAC10.html) 2006-04-20

Family

ID=21853121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000533099A Pending JP2002504505A (ja) 1998-02-25 1999-02-25 ブトルファノール持続放出性製剤

Country Status (8)

Country Link
US (1) US6197344B1 (cg-RX-API-DMAC10.html)
EP (1) EP1056443B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002504505A (cg-RX-API-DMAC10.html)
AT (1) ATE265846T1 (cg-RX-API-DMAC10.html)
AU (1) AU753278B2 (cg-RX-API-DMAC10.html)
CA (1) CA2321924A1 (cg-RX-API-DMAC10.html)
DE (1) DE69917000T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999043300A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680067B2 (en) * 2001-11-26 2004-01-20 Oliver Yoa-Pu Hu Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
RU2254852C1 (ru) * 2004-01-23 2005-06-27 Ефим Давыдович Нежинский Раствор для инъекций, обладающий выраженным анальгетическим действием, и способ его получения
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
CA2816420C (en) * 2010-10-29 2018-01-16 Najib Babul Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
JP6935393B2 (ja) 2015-05-28 2021-09-15 ルモサ セラピューティクス カンパニー, リミテッド セバコイルジナルブフィンエステルの徐放のための医薬製剤
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US10183018B2 (en) 2015-05-28 2019-01-22 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
CN111904928A (zh) * 2019-05-07 2020-11-10 江苏恒瑞医药股份有限公司 一种包含布托啡诺的可注射的药物组合物及其制备方法
CN116818928B (zh) * 2023-04-28 2024-04-19 杭州沐源生物医药科技有限公司 一种酒石酸布托啡诺注射液中杂质的分离检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788478A (fr) 1971-09-08 1973-03-06 Bristol Myers Co Procede de preparation de composes analgesiques
CA1098444A (en) * 1975-05-26 1981-03-31 Leo Geller Peptide preparations with prolonged action
US4338324A (en) * 1981-03-17 1982-07-06 Mcneilab, Inc. Analgesic potentiation
US4322427A (en) 1981-04-16 1982-03-30 Bristol-Myers Company Analgetic compositions and methods of use
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DK175572B1 (da) * 1987-07-24 2004-12-13 Nexstar Pharmaceuticals Inc Anvendelse af phospholipidkapsler til indkapsling af et opoid-analgetika
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
JP2596255Y2 (ja) 1993-03-23 1999-06-07 ナカミチ株式会社 ディスク再生装置
DE69603577T2 (de) 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Similar Documents

Publication Publication Date Title
US20260041775A1 (en) Compositions for drug administration
US11173209B2 (en) Compositions for drug administration
JP3274687B2 (ja) 9−ヒドロキシリスペリドン脂肪酸エステルの水性懸濁物
JP4892148B2 (ja) 活性物質ジアモルフィンからなる医薬生成物およびオピエート嗜癖の処置方法におけるその使用
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
JP2007507538A5 (cg-RX-API-DMAC10.html)
CA2601289A1 (en) Once-a-day oxycodone formulations
JP2005515966A (ja) 鎮痛薬としての使用のための6−ヒドロキシ−オキシモルホンの経口投与
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
WO2006039692A3 (en) Modified release ibuprofen dosage form
NZ519993A (en) Compositions for delivery of a cortisol antagonist
JPH08508049A (ja) 眼科用組成物におけるビタミンeトコフェリル誘導体の使用
JP2002519425A5 (cg-RX-API-DMAC10.html)
CA2366841A1 (en) Tolperisone-containing pharmaceutical preparation for oral administration
JP5116665B2 (ja) 口腔投与のためのアポモルフィンの薬学的配合物
JP2003534246A5 (cg-RX-API-DMAC10.html)
WO2003004024A1 (en) Injectable sustained-release microspheres of huperzine a compounds
KR101307650B1 (ko) 구역에 대한 경피 방법 및 패치
JP2000273061A (ja) テルペノイドエマルション
JP2002537232A5 (cg-RX-API-DMAC10.html)
SK134395A3 (en) Transdermal therapeutical agent and preparation method thereof
HU227338B1 (en) Pharmaceutical compositions of alkylsulphonamides 5ht1 agonists for rectal administration
US20180000942A1 (en) Compositions for drug administration
JP2002523458A5 (cg-RX-API-DMAC10.html)